MedTrace Logo

Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)

NCT01104987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2016-08-09

No results posted yet for this study

Summary

This prospective study will assess the effects of treatment with alendronate in osteoporotic patients with ankylosing spondylitis.

Primary objectives:

* To investigate if alendronate effect bone mineral density (BMD) assessed by dual energy x-ray absorptiometry (DXA) in lumbar spine, hip and distal forearm and assessed by quantitative computed tomography (QCT) in lumbar spine and by Xtreme CT in radius and tibia.

Secondary objectives:

* To investigate if alendronate effects markers of bone remodeling
* To investigate if alendronate influences disease activity (BASDAI), spinal function (BASFI), spinal movement (BASMI) and health related quality of life (SF-36).

Conditions

Interventions

DRUG

alendronate

One tablet of alendronate à 70 mg once a week during two years.

Sponsors & Collaborators

  • Göteborg University

    lead OTHER

Principal Investigators

  • Helena Forsblad d'Elia, MD, PhD · Sahlgrenska Academy at University of Gothenburg, Department of Rheumatology and Inflammation Research

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01104987 on ClinicalTrials.gov